GALMED PHARMACEUTICALS WKN: A1XFUX ISIN: IL0011313900 Kürzel: GPH Forum: Aktien Thema: Hauptdiskussion

Du brauchst mehr Geduld!

Echt schwach die Reaktion am markt schade.

brauch 1,52 für plus...

... gewesen ...

Drüber 😊

wir müssen über 1,42$

😊

1,30$ is the key

abwarten…..

Das klingt so gut aber steigt nicht nachhaltig sondern fällt gleich wieder. Wie schade. War kurz um plus...

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect of Bayer's top selling cancer drug, Stivarga® (regorafenib); such combination could potentially become a life-cycle IP strategy when Stivarga's® main European and U.S. patents expires in August 2028 and July 2032, respectively. New patent applications (US 63/786,370 and US 63/915,832) have been submitted to USPTO. Metformin is typically the first-choice treatment for managing type 2 diabetes and is widely available in generic forms. The combination of Aramchol and Stivarga® is expected to enter phase 1b clinical trials early 2026 in metastatic colorectal cancer (CRC), hepatocellular (HCC) and cholangiocarcinoma patients with a planned expansion cohort including metformin.

🥁

….

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro 🤫

Grad gute einkaufskurse oder?